Erick Bournigal, MD
Rheumatology · Brunswick, GANPI 1275548547
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,107 of the $21,996 with a category attached, or 68.7%. 41 manufacturers reported payments, led by Amgen at 36.5% of the total. Reporting peaked in 2022 at $8,442 and has fallen 55.0% since, to $3,797 in 2025.
Across 694 payments — averaging $31.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- AbbVie$3K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- Sanofi$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $5K from 35 others
What the payments were for
- Consulting fees$8104%
- Speaking & faculty fees$4,38020%
- Grants$2401%
- Travel & lodging$9544%
- Food & beverage$15,10769%
- Education$5052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,996 in reported general payments places this provider in the 85th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 16 | $690,570 |
| RinvoqUpadacitinib | 95 | $679,588 |
| Enbrel SureclickEtanercept | 60 | $508,083 |
| Enbrel MiniEtanercept | 66 | $488,690 |
| Humira(Cf) PenAdalimumab | 31 | $271,137 |
| Taltz AutoinjectorIxekizumab | 25 | $267,947 |
| Humira(Cf)Adalimumab | 30 | $266,093 |
| KevzaraSarilumab | 62 | $262,555 |
| TymlosAbaloparatide | 99 | $262,381 |
| TremfyaGuselkumab | 11 | $149,330 |
| Xeljanz XrTofacitinib Citrate | 18 | $111,055 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $109,096 |
| EnbrelEtanercept | 15 | $108,813 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $78,879 |
| OrenciaAbatacept | 12 | $67,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Vraylar, Savella | $2,592 | $1,012,953167 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $1,068 | $690,57016 claims |
| SanofiKevzara | $1,279 | $262,55562 claims |
| Radius Health, Inc.Tymlos | $471 | $262,38199 claims |
| Johnson & JohnsonTremfya | $2,131 | $149,33011 claims |
| AmgenEnbrel | $8,038 | $108,81315 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,543 | $78,87915 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $24 | $67,60512 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $27 | $14,00311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Uloric | $109 | $3,64912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Brunswick
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
- Mohammed AbubakerMarietta$218K
- James HuntThomasville$160K
- Omar KhanCumming$145K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.